Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006

被引：63

作者：

Furst, D. E.

Breedveld, F. C.

Kalden, J. R.

Smolen, J. S.

Burmester, G. R.

Emery, P.

Keystone, E. C.

Schiff, M. H.

van Riel, P. L. C. M.

Weinblatt, M. E.

Weisman, M. H.

机构：

[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90025 USA

[2] Leiden Univ, Med Ctr, Dept Rheumatol, NL-2300 RA Leiden, Netherlands

[3] Univ Erlangen Nurnberg, Inst Clin Immunol, Dept Internal Med 3, D-8520 Erlangen, Germany

[4] Vienna Gen Hosp, Inst Rheumatol, Clin Internal Med 3, Vienna, Austria

[5] Charite Hosp, Dept Rheumatal & Clin Immunol, Berlin, Germany

[6] Univ Leeds, Gen Infirm, Dept Rheumatol, Leeds LS1 3EX, W Yorkshire, England

[7] Mt Sinai Hosp, Dept Rheumatol, Toronto, ON M5G 1X5, Canada

[8] Denver Arthrit Clin, Denver, CO USA

[9] Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[10] Brigham & Womens Hosp, Boston, MA 02115 USA

[11] Cedar Sinai Hosp, Los Angeles, CA USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷

关键词：

D O I：

10.1136/ard.2006.061937

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2 / 15

页数：14

共 264 条

[61]

CUSH J, ACR HOTLINE 2002

[62] Results from an open-label extension study of etanercept in ankylosing spondylitis [J].

Davis, J ;

Webb, A ;

Lund, S ;

Sack, K .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2004, 51 (02) :302-304

[63] Recombinant human tumor necrosis factor receptor, (etanercept) for treating ankylosing spondylitis - A randomized, controlled trial [J].

Davis, JC ;

van der Heijde, D ;

Braun, J ;

Dougados, M ;

Cush, J ;

Clegg, DO ;

Kivitz, A ;

Fleischmann, R ;

Inman, R ;

Tsuji, W .

ARTHRITIS AND RHEUMATISM, 2003, 48 (11) :3230-3236

[64] Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy [J].

De Rycke, L ;

Kruithof, E ;

Van Damme, N ;

Hoffman, IEA ;

Van den Bossche, N ;

Van den Bosch, F ;

Veys, EM ;

De Keyser, F .

ARTHRITIS AND RHEUMATISM, 2003, 48 (04) :1015-1023

[65] Anakinra for flares of pyogenic arthritis in PAPA syndrome [J].

Dierselhuis, MP ;

Frenkel, J ;

Wulffraat, NM ;

Boelens, JJ .

RHEUMATOLOGY, 2005, 44 (03) :406-408

[66] Frequency of infection in patients with rheumatoid arthritis compared with controls - A population-based study [J].

Doran, MF ;

Crowson, CS ;

Pond, GR ;

O'Fallon, WM ;

Gabriel, SE .

ARTHRITIS AND RHEUMATISM, 2002, 46 (09) :2287-2293

[67] SULFASALAZINE IN THE TREATMENT OF SPONDYLARTHROPATHY - A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY [J].

DOUGADOS, M ;

VANDERLINDEN, S ;

LEIRISALOREPO, M ;

HUITFELDT, B ;

JUHLIN, R ;

VEYS, E ;

ZEIDLER, H ;

KVIEN, TK ;

OLIVIERI, I ;

DIJKMANS, B ;

BERTOUCH, J ;

BROOKS, P ;

EDMONDS, J ;

MAJOR, G ;

AMOR, B ;

CALIN, A .

ARTHRITIS AND RHEUMATISM, 1995, 38 (05) :618-627

[68] Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes [J].

Edwards, JCW ;

Cambridge, G .

RHEUMATOLOGY, 2001, 40 (02) :205-211

[69] Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis [J].

Edwards, JCW ;

Szczepanski, L ;

Szechinski, J ;

Filipowicz-Sosnowska, A ;

Emery, P ;

Close, DR ;

Stevens, RM ;

Shaw, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) :2572-2581

[70]

Ehresmann GR, 2002, ARTHRITIS RHEUM-US, V46, pS160

← 2 3 4 5 6 7 8 9 10 11 →